http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia
Milawaty Nurjono,Jimmy Lee,Siow-Ann Chong 대한정신약물학회 2012 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.10 No.2
Brain-derived neurotrophic factor (BDNF), a neurotrophin known to be responsible for development, regeneration, survival and maintenance of neurons has been implicated in the pathophysiology of schizophrenia. This review seeks to complement previous reviews on biological roles of BDNF and summarizes evidence on the involvement of BDNF in the pathophysiology of schizophrenia with an emphasis on clinical relevance. The expressions of BDNF were altered in patients with schizophrenia and were found to be correlated with psychotic symptomatology. Antipsychotics appeared to have differential effects on expression of BDNF but did not restore BDNF expression of patients with schizophrenia to normal levels. In addition, evidence suggests that BDNF is involved in the major neurotransmitter systems and is associated with disruptions in brain structure, neurodevelopmental process, cognitive function, metabolic and immune systems commonly associated with schizophrenia. Besides that, BDNF has been demonstrated to be tightly regulated with estrogen which has also been previously implicated in schizophrenia. Evidence gathered in this review confirms the relevance of BDNF in the pathophysiology of schizophrenia and the potential utility of BDNF as a suitable biomarker for diagnostic and prognostic purposes for disease outcome and other co-morbidities. However, further investigations are warranted to examine the specificity of BDNF in schizophrenia compared to other neurodegenerative disorders and other neuropsychiatric illness. Longitudinal prospective studies will also be of added advantage for evaluation of prognostic utility of BDNF in schizophrenia.
Regulation of Interleukin-6 and Leptin in Schizophrenia Patients: A Preliminary Analysis
Sasi Neelamekam,Jimmy Lee,Milawaty Nurjono 대한정신약물학회 2014 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.12 No.3
Objective: Immune-inflammatory mediators play a pivotal role in brain signaling and have been increasingly associated withthe pathophysiology of schizophrenia. Many studies have indicated an increased level of immune-inflammatory interleukin-6(IL-6) in schizophrenia. IL-6 is a well-known chief stimulator of inflammation. Of late leptin has also been implicated in theinflammatory pathway of schizophrenia. In this study we measured and compared serum levels of IL-6 and leptin in patientswith schizophrenia to healthy controls, and investigated the relationship between IL-6 and leptin. Methods: Serum IL-6 and leptin were determined in 20 patients diagnosed with schizophrenia and in 19 healthy controls matchedby gender, age and body mass index (BMI) using commercial Bioplex assays. Results: Using Mann-Whitney U-test, significantly increased IL-6 levels were found in the patients but there was no significantdifference in leptin levels though a trend towards higher leptin was observed in the patients. Spearman correlations did notshow any correlation between IL-6 and clinical variables except antipsychotic dosage. Leptin significantly correlated with genderand BMI. A large effect size correlation was observed between IL-6 and leptin in the patients but not in the controls. Multipleregression analysis performed on patients, after adjusting for gender and BMI, revealed there was no significant associationbetween IL-6 and leptin. Conclusion: IL-6 and leptin levels may reflect the chronic inflammatory state associated with schizophrenia but further evaluationis required. Also, it is important to consider the confounding effects of obesity in any examination of relationships between groupswith regard to cytokines and adipokines.